Reshma Rangwala is VP at Karyopharm Therapeutics Inc. (KPTI). They have made 9 open-market trades across 1 company since 2023, most recently 2026-05-14.
CIK 0001825322
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KPTI | 56,829 | $22K |
Shares reported on the most recent Form 4, priced at the 2026-05-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KPTI | SELL | 2026-05-14 | 2026-05-15 | $9.50 | $4K | +17.1% | +23.6% | -74.5% |
| KPTI | SELL | 2026-04-21 | 2026-04-22 | $8.94 | $4K | -3.3% | -15.0% | -17.8% |
| KPTI | SELL | 2026-03-02 | 2026-03-03 | $9.41 | $48K | -13.9% | -35.4% | +7.7% |
| KPTI | SELL | 2025-09-15 | 2025-09-16 | $6.43 | $3K | +5.3% | -3.1% | +7.9% |
| KPTI | SELL | 2025-04-23 | 2025-04-24 | $6.17 | $3K | +7.9% | -21.7% | -16.4% |
| KPTI | SELL | 2025-03-04 | 2025-03-06 | $6.29 | $23K | -6.6% | -35.3% | -30.4% |
| KPTI | SELL | 2024-04-22 | 2024-04-23 | $1.17 | $8K | +2.7% | -0.9% | -17.2% |
| KPTI | SELL | 2024-02-29 | 2024-03-04 | $1.18 | $25K | +1.5% | -2.7% | -25.2% |
| KPTI | SELL | 2023-04-20 | 2023-04-24 | $4.05 | $27K | -31.1% | -37.8% | -59.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.